Methods of designing, generating, screening, and identifying one or more of these peptides possessing multiple functionalities, for example, including (i) high binding to a cellular target (e.g., melanin pigment in the eye), (ii) high cell-penetration (e.g., to enter cells and access melanin in the melanosomes), and (ii) low cytotoxicity have been developed. Peptides or drug conjugates thereof having these multiple functionalities are particularly effective for selective delivery, prolonged residence, and sustained release of active agents to the epithelial tissues via mucosal surfaces. Methods of using these peptides are also described.

Provided is a sensor device, comprising: a portion of graphene and/or graphene oxide in electronic communication with a gold source electrode, a drain electrode, a gate electrode, or any combination thereof; and an aptamer in electrical communication with the portion of graphene and/or graphene oxide, the portion of graphene and/or graphene oxide connected to said aptamer via at least one linker that comprises 4-carboxybenzenediazonium tetrafluoroborate.

Disclosed is a switching peptide that can be applied to an optical one-step immunoassay method. The switching peptide comprises: a peptide compound capable of reversibly binding to a binding antibody; and a fluorescent marker bound to the peptide compound.

Provided herein is a family of cyclic peptides that exhibit specific affinity to EGFR expressing cells, and that can be used as drug delivery vehicle for labeling agents and cytotoxic drugs against said cells in the context of a peptide-drug conjugates, as well as pharmaceutical compositions including the same, and uses thereof for treating cancer.

The invention relates to a novel chemical compounda diagnostic markerfor use in medicine, more specifically in cancer diagnosis, in particular the diagnosis of uterine body cancer. The invention also relates to an in vitro method for detecting enzymatic activity present in a subject's body fluid, in particular derived from uterine body cancer cells, using the compound. The invention further relates to an in vitro method for diagnosing uterine body cancer using the compound, a kit comprising the compound and use of the compound for the detection of enzymatic activity specific to uterine body cancer and use of the compound for the diagnosis of uterine body cancer. The invention also relates to the compound for use as a diagnostic marker of uterine body cancer and a method for the treatment of uterine body cancer comprising a step of carrying out the method for the diagnosis of uterine body cancer as defined above using the compound.